Information Provided By:
Fly News Breaks for July 18, 2016
RLYP
Jul 18, 2016 | 07:01 EDT
Brean Capital believes Relypsa is an attractive acquisition target with a promising drug in early development. The firm said the June Veltassa prescription data was very promising, noting as well that the company said they will now report sales on the drug on a quarterly, rather than on a monthly, basis. Brean Capital reiterated its Buy rating and $26 price target on Relypsa shares.
News For RLYP From the Last 2 Days
There are no results for your query RLYP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.